Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
54 PLN | -0.37% | -0.37% | -6.09% |
May. 17 | Transcript : Ryvu Therapeutics S.A. - Special Call | |
Mar. 13 | Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 90.5M 23.02M | Sales 2025 * | 132M 33.66M | Capitalization | 1.25B 318M |
---|---|---|---|---|---|
Net income 2024 * | -162M -41.21M | Net income 2025 * | -140M -35.61M | EV / Sales 2024 * | 13.5 x |
Net cash position 2024 * | 26.93M 6.85M | Net Debt 2025 * | 65.62M 16.69M | EV / Sales 2025 * | 9.93 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.75% |
Latest transcript on Ryvu Therapeutics S.A.
1 day | -0.37% | ||
1 week | -0.37% | ||
1 month | +11.11% | ||
3 months | -5.43% | ||
6 months | -8.47% | ||
Current year | -6.09% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 06-12-31 | |
Hendrik Nogai
CTO | Chief Tech/Sci/R&D Officer | - | 22-01-31 |
Chief Operating Officer | 38 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | - | |
Scott Fields
BRD | Director/Board Member | 69 | 23-06-13 |
Thomas Turalski
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 54 | -0.37% | 832 |
24-06-05 | 54.2 | -1.28% | 1,696 |
24-06-04 | 54.9 | +1.67% | 3,913 |
24-06-03 | 54 | 0.00% | 1,597 |
24-05-31 | 54 | -0.37% | 2,844 |
Delayed Quote Warsaw S.E., June 06, 2024 at 11:55 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-6.09% | 317M | |
+19.33% | 125B | |
+13.95% | 109B | |
-3.53% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-12.62% | 16.64B | |
+0.99% | 13.45B | |
+21.79% | 11.32B |
- Stock Market
- Equities
- RVU Stock